SCHEMBL4712490

SCHEMBL4712490

Cc1cccc(C=Cc2ccncc2)n1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.73
ALDH1A1 P00352 3/20 0.73
GRM4 Q14833 3/20 0.73
RAB9A P51151 3/20 0.73
SMN1; SMN2 Q16637 3/20 0.73
KDM4E B2RXH2 3/20 0.73
HPGD P15428 3/20 0.73
MEN1 O00255 2/20 0.73
CYP3A4 P08684 2/20 0.73
CYP2D6 P10635 2/20 0.73
CYP2C9 P11712 2/20 0.73
CYP2C19 P33261 2/20 0.73
KMT2A Q03164 2/20 0.73
GRM5 P41594 2/20 0.73
NPSR1 Q6W5P4 1/20 0.73
HDAC6 Q9UBN7 1/20 0.73
PKM P14618 1/20 0.73
TSHR P16473 1/20 0.73
NFKB1 P19838 1/20 0.73
THPO P40225 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4711058 1.00 NPC1 (0.73) NPC1ALDH1A1GRM4RAB9ASMN1; SMN2
SCHEMBL29510104 0.85 GRM4 (1.00) NPC1ALDH1A1GRM4RAB9ASMN1; SMN2
SCHEMBL350949 0.85 GRM4 (1.00) NPC1ALDH1A1GRM4RAB9ASMN1; SMN2
SCHEMBL179801 0.85 GRM4 (1.00) NPC1ALDH1A1GRM4RAB9ASMN1; SMN2
SCHEMBL4712658 0.84 RAB9A (0.76) NPC1ALDH1A1GRM4RAB9ASMN1; SMN2
SCHEMBL4711246 0.83 KDM4E (0.76) NPC1ALDH1A1GRM4RAB9ASMN1; SMN2
SCHEMBL4711247 0.83 KDM4E (0.76) NPC1ALDH1A1GRM4RAB9ASMN1; SMN2
SCHEMBL4712060 0.81 NPC1 (0.67) NPC1ALDH1A1GRM4RAB9ASMN1; SMN2
SCHEMBL4712059 0.81 NPC1 (0.67) NPC1ALDH1A1GRM4RAB9ASMN1; SMN2
SCHEMBL4711084 0.80 ALDH1A1 (0.71) NPC1ALDH1A1GRM4RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP claimed
CN-1262676-A Pyridine derivatives NOVARTIS AG (CH) 2000-08-09 CN claimed
EP-0998459-A2 PYRIDINE DERIVATIVES Novartis AG (CH) 2000-05-10 EP claimed
WO-1999002497-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 1999-01-21 WO claimed
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP disclosed
CN-1203060-C Pyridine derivatives, compositions and uses thereof NOVARTIS AG (CH) 2005-05-25 CN disclosed
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed
CN-1262676-A Pyridine derivatives NOVARTIS AG (CH) 2000-08-09 CN disclosed
EP-0998459-A2 PYRIDINE DERIVATIVES Novartis AG (CH) 2000-05-10 EP disclosed
WO-1999002497-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 1999-01-21 WO disclosed